The preferential usage of certain T cell receptor (TCK) V3 genes has been well established in several major histocompatibility complex (MHC)-restricted immune responses. However, V3 usage among allogeneic responses remains unclear. Because recent findings of ours and others indicate that V38 predominates in certain La-restficted, peptide-spedfic responses, we examined the V38 usage in allogendc responses to L a. To selectively recognize the L a molecule, cells from BALB/c-H-2 am (din2), the La-loss mutant mouse, were stimulated in vitro or in vivo with wildtype BALB/c cells. We report here that after the intraperitoneal administration of the anti-V38 monoclonal antibody (mAb) F23.1, peripheral V/~8 T cells were depleted from din2 mice. This in vivo depletion abrogated the ability of dm2 splenocytes to mount a primary response to L a molecules. This abrogation was specific, since the response of V/~8-depleted dm2 cells to Kb/D b antigens was the same as that of control nondepleted dm2 cells. Furthermore, in vivo depletion of V38 cells was found to cause a dramatic prolongation of La-disparate skin grafts (mean survival time [MST] 22.1 _+ 2.1 vs. 10.3 _+ 1.1 d for saline-treated controls, or 10.9 _+ 1.7 d for controls treated with mAb KJ23 to V/317). By contrast, V/38 depletion had no effect on recipients grafted with haplotype-mismatched skin or single Dk-locus-disparate skin. These findings demonstrate that V38 + T cells predominate in allogendc response to L a but not other alloantigens. The effect of V38 depletion was found to be even more dramatic on recipients grafted with La-disparate vascularized heart transplants (MST > 100 vs. 8.6 _+ 0.5 d for controls). In total, these findings establish the efficacy of using mAb to the V3 gene family to specifically and significantly enhance the survival of allografts. The implications of detecting V38 usage in both alloreactive or MHC-restricted TCR responses to the same class I molecule are discussed.
T
he function of the immune system is to discriminate self from non-self. For example, the cellular arm of the immune system identifies virus-infected cells, malignant cells, or genetically disparate tissue transplants using CD8 + CTL. These CTL bear receptors (TCK) capable of specific identification of appropriate target cells that express foreign peptides bound to self-class I MHC molecules (1) . Such immunogenic peptides are 8-9 amino acids long and are bound to the antigen binding groove formed by the or1 and oe2 domains of the class I molecule (2) . The TCK is a disulfidelinked orb heterodimeric glycoprotein with a number of invariant associated molecules (3, 4) . The heterogeneity of TCK molecules that is required to recognize the abundance of potential foreign antigens is achieved by somatic recombination of V-(D)-J segments to form a single functional transcriptional unit encoding each ot or 3 TCR chain. Since there are several different alternative V-(D)-J segments, as well as additional junctional diversities, innumerable distinct TCR are generated, each with unique structures (5) (6) (7) . Even though it is dear that structural differences in both TCR o~ and 3 chains determine their specific interaction with MHC-peptide complexes, the details have yet to be fully elucidated. Recent data support a model whereby distinct regions of each o~ and/3 chain interact with the MHC molecule or its bound peptide ligand (7) .
Given the large number of different combinational TCR possibilities, as well as the various manners by which TCR and MHC-peptide complexes potentially interact, it might be expected that most immune responses would show diverse TCR usage. However, some interesting examples of limited TCR usage have recently been noted. For instance, the Ld-restricted immune response of a BALB/c mouse after CMV infection was shown to preferentially use VB8 + T cells (8) . Similarly, predominant V38 usage was also observed in studies of La-restricted CTL specific for the tumor-associated tum-peptide (Solheim, J. C., M. A. AlexanderMiller, J. M. Martinko, andJ. M. Connolly, manuscript submitted for publication). In studies of Ka-restricted responses, CTL specific for a single Plasraodium berghei circumsporozoitederived peptide displayed diverse TCR (9) in contrast to ones specific for an HLA-CW3 peptide that display limited TCR diversity (10) . The structural basis for why particular immune responses have been found to show limited TCR usage remains unclear.
Our understanding of the diversity of TCR usage in allogeneic responses to class I, such as allograft rejection, is potentially important for both mechanistic and therapeutic reasons. However, allogeneic recognition of class I has an additional level of complexity compared with the syngeneic systems mentioned above. This uncertainty stems from the fact that it remains unclear whether alloreactive T cells recognize predominantly polymorphic MHC determinants or their bound ligands. If bound ligands play a key role in allorecognition, then tissue-specific antigens could significantly influence the diversity of alloreactive CTL involved in allograft rejection. Initial studies analyzing TCR gene usage during endstage transplantation rejection episodes or in vitro allorecognition have been conflicting. Certain studies have demonstrated the preferential usage of specific TCR variable regions (11, 12) , whereas others have reported high levels of diversified gene usage (13) (14) (15) . It is dit~cult to understand the implication of these studies on TCR diversity because of the expression of multiple major and minor alloantigenic differences between host and donor tissue. To alleviate this problem, we have investigated the in vitro and in vivo response to a single class I alloantigen, the L d molecule of the mouse. Studies of allorecognition using L a have two notable advantages. First, La-spedfic responses can be generated using the Ld-loss mutant (16) mouse strain BALB/c-H-2 ~2 (dm2) t. Second, we and others (8; Solheim et al., manuscript submitted for publication) have generated a background of relevant information concerning the TCR recognition of Ld-peptide complexes in syngeneic immune responses.
In this communication, we demonstrate that the in vivo depletion of the V~8 + T cell subset results in a significant decrease in the dm2 anti-L a allogeneic response. Furthermore, recipient din2 mice depleted of V/38 + cells show dramatic and specific prolongation of skin or heart allograft survival. These findings thus represent a dear example of dominant V~ usage in an in vivo primary response to a class I alloantigen. The implications of these findings on TCR recognition of allogeneic versus syngeneic class I-pcptide complexes are discussed.
Materials and Methods
Animals. Female C57BL/6, BALB/c, B10.HTT, BALB.K, (B10.AKM x dm2)F1, and BALB/c-H-2 d~ (din2) mice (see Table  1 ) were bred and maintained in the animal facility of Donald C.
Shreffler, Washington University School of Medicine. All mice were used at 6-12 wk of age and were cared for according to National Institutes of Health guidelines.
Tumor Target Cell Lines. The mastocytoma P815, lymphoma EL-4, thymoma R1.1, and Ld-transfected thymoma RI.IL d (see Table 1 ) were maintained at 37~ 95% air/5.0% CO2 in DME (Gibco Laboratories, Grand Island, NY) containing 10% FCS (Hyclone Laboratories, Logan, UT), 2 mM r-glutamine, and 100 U/ml penicillin-streptomycin (Washington University Tissue Culture Center).
mAb Usedforln Vivo Depletions. The anti-V~8 mAb F23.1 (17) , and anti-VB17 mAb KJ23 (18) (generously provided by Dr. O. Kanagawa, Department of Pathology, Washington University) are mouse IgG2a isotype that were grown in our laboratory as culture supernatant and ascites fluid and were protein A af~nity chromatography purified.
In Vivo Depletion of V~8 + T Cells. Groups of three identically treated experimental dm2 mice received three independent 500/~g i.p. injections of protein A-purified F23.1 mAb in 0.5 ml normal saline (days 0, + 2, and + 4) before harvesting of splenocytes (day + 7) for analysis via flow cytometry (FACS| Becton Dickinson & Co., Mountain View, CA). Control dm2 mice received intraperitoneal injection of the vehicle, 0.5 ml 0.9% normal saline without F23.1 before splenocyte harvest and analysis.
Flow Cytometry. Briefly, 2-4 x 10 s cells were plated in the wells of round-bottomed microtiter phtes, washed once with HBSS (lacking phenol red) containing 0.2% FCS/0.1% sodium azide (FACS | medium), and were incubated with a saturating concentration ofF23.1 n'LAb, biotinylated anti-CD8 (Ly2) (Pharmingen, San Diego, CA), or with FACS | medium alone for 30 min at 4~ The cells were washed three times with FACS | medium, and then incubated with a saturating concentration of fluorescein-conjugated F (ab')2 fragment of Fc-specific goat anti-mouse IgG, (OrganonTeknika-Cappel, Durham, NC) or Streptavidin-PE (Caltag Laboratories, South Francisco, CA) for 30 rain at 4~ washed with FACS | medium three times, and finally resuspended in 0.5 ml FACS | medium. Fhorescein and PE-labded calls were analyzed using a FACScan | (Becton Dickinson & Co.) equipped with an argon hser tuned to 488 nm and operating at 150 mW of power. Fluorescent four-quadrant, two-color contour plots were generated with logarithmic amplification of fluorescence emitted by single viable cells. Each sample analyzed comprised a minimum of 2.5 x 104 ceils and was statistically evaluated using the CONSORT 30 computer software (Becton Dickinson & Co.).
Generation of Specific din2 Anti-H-2L ~ CTL. Splenocytes used for the generation of primary din2 anti-H-2L d CTL were harvested from control saline-or F23.1-treated dm2 mice 7 d after the initial intraperitoneal injection of the mAb F23.1. At the completion of BALB/c skin graft rejection, spleen cells used for the generation of secondary dm2 anti-H-2L d CTL were harvested from control saline-and F23.1-treated dm2 recipient mice. 7.5 x 106 responding spleen cells were cecultured in 24-well tissue culture plates (Costar Corp., Cambridge, MA) with 3.5 x 106 irradiated (2,000 tad) stimulating BALB/c spleen cells at 37~ 95% air/5% COz for 5 d in a final vohme of 2 ml. At the completion of this incubation period, effector cells were harvested, washed, and resuspended in DME supplemented with 10% FCS.
SlCr-Release Assay. 104 target ceils were labeled with 200/~Ci StCr (NaSlCrO+, 1 mCi/ml; Amersham Corp., Arlington Heights, IL) in 100 ~1 of DICE supplemented with 10% FCS for 1 h at 37~ in 95% air/5% CO~. Radiolabeled target ceils were washed three times, counted, and resuspended. 2 x 103 calls in 100/zl DME with 10% FCS were added to V-bottomed microtiter plates (ICN Biomedicals, Inc., Costa Mesa, CA). For antibody blocking, 10/~g of F23.1 was added 15 min before the addition of the respective targets and remained throughout the 4-h SlCr-release assay.
Effector cells were harvested, resuspended, diluted to the appropriate concentration, and dispensed into the V-bottomed plates. The plates were spun at 50 g for 2 rain and incubated for 4 h at 37~ and 95% air/5% CO2. At completion of the incubation period, the plates were spun at 500 g and 100 t~l of the supematant was harvested and counted on a gamma counter (model 1272 Clinigamma; LKB Instruments, Turku, Finhnd). The mean of triplicate samples was calculated and percent SlCr-release was determined according to the following equation: percent SlCr-release 9 , 100x [(experimental SlCr-release -control SlCr-release)/ (maximum StCr-release -control SlCr-rehase)]. Where experimental SlCr-release represents counts from target cells mixed with effector cells, control S*Cr-release represents counts from target cells incubated with medium alone (spontaneous release), and maximum SlCr-release represents counts from target cells exposed to 5% Triton X-100. For data presented in this paper, the SEM percent lysis was <5% of the value of the mean.
Skin Grafting. Female din2 and (B10.AKM x dm2)F1 mice were engrafted on the left and right dorsal thorax with full thickness abdominal B10.HTT, C57BL/6, BALB.K, or BALB/c skin grafts on day 0 according to an adaptation of the method of Billingham and Medawar (19) . On days -2, 0, and +3, experimental din2 mice were injected intraperitoneally with 500/~g aifinitypurified F23.1 mAb, while control din2 mice received an intraperitoneal injection of 0.5 ml normal saline without F23.1, or 500/~g of the isotype-matched mAb KJ23 (anti-V317). Bandages were removed on day + 7, and the grafts were scored daily until rejection was complete (defined as loss >90% of the grafted tissue).
Cardiac Transplantation. Intraabdominal heterotopic cardiac transplantation was performed according to a modified method of Corry et al. (20) .
BALB/c donors received 300 U of heparin intravenously 10 rain before surgery. The superior and inferior vena cavae were ligated and the heart perfused with 2 ml of 4~ lactated Ringer's solution via the inferior vena caw. The pulmonary artery was divided at its bifurcation and the ascending aorta transected proximal to the origin of the innominate artery. After mass ligation of the pulmonary veins, the heart was removed and stored in 4~ lactated Ringer's solution.
The donor's ascending aorta was anastomosed end to side to the recipient infrarenal abdominal aorta with a running 10-0 dermalon suture (courtesy of Davis & Geck, Co., Danbury, CT). The donor pulmonary artery was anastomosed end to side to the recipient inferior vena caw with a 10-0 dermalon suture in a running fashion. Graft ischemia was consistently <20 min, and all grafts began beating promptly after revascularization. Graft function was assessed by daily cardiac palpation, and graft rejection, defined as complete cessation of ventricular contraction, was confirmed histologically.
Statistical Analysis of Cardiac Allognafi and Skin Gnarl Survival
Data. Allograft survival data were evaluated for statistical significance by the Kaphn-Meier analysis, and considered significant at p < 0.05. TCR in syngeneic CTL responses to L d plus peptide, we sought to define the role of V~8 + CTL in aUogeneic responses. Primary CTL specific for L a were generated using splenic lymphocytes from the Ld-loss mutant din2 as responders and irradiated wild-type BALB/c splenocytes as stimulators. To determine whether V/38 + CTL were involved in this response to L a, the anti-V/J8 mAb F23.1 was added to the 4-h SlCr-release assay to block target cell recognition. In the experiment shown in Fig. 1 a, the mAb F23.1 was found to block CTL recognition of L d by •80%o. Furthermore, this blocking was specific since the din2 response to Kb/D b molecules was not blocked by F23.1 ( Fig.  1 b) . Even though specific blocking of L d by F23.1 was observed in three of four experiments, the level of blocking was variable (range 30, 60, and 80%). It is noteworthy, however, that better blocking was observed if F23.1 mAb was added to both the sensitization and assay cultures (data not shown). does not block ef~ciently. For these studies we utilized the Ld-transfected thymoma target ILl.1 which is FctL negative, thus ruling out the possibility of FcR-mediated redirected lysis. Therefore, poor blocking could be attributed to either F23.1 having a lower affinity for V138 than V~8 has for L d, or that the F23.1 site on V~8 is sterically distinct from that involved in L a recognition. To resolve this issue we used F23.1 in vivo depletion of V138 ceils (21) to determine the extent of the contribution of V/38 + T ceils to the generation of a primary response to L a.
Results

Blocking of the In Vitro
Effect of In Vivo Administration of the mAb f:23.1. To in vivo deplete the V/38 + T lymphocytes, din2 mice were given three 500-#g i.p. injections of affinity-purified 1:23.1 mAb on days 0, 2, and 4. Approximately 72 h after the third injection, the spleen cells were harvested, pooled, and analyzed for the expression of the V/38 TCK and CDS. Whereas in control din2 mice, 5-7% of the peripheral spleen cells were found to be V/38 + CD8 +, the F23.1-treated dm2 mice showed virtually complete depletion of all CD8 + V/$8 + T lymphocytes (Fig. 2) . Similar results were seen in five independent cytometry experiments run as controls for subsequent CTL and aUograft studies. It should be noted that after F23.1 treatment, staining with the secondary fluoresceinconjugated goat anti-mouse IgG alone was negative on V/38 § T ceils. This result indicates that the failure to detect V/38 + T ceils was not due to to antibody blocking by the F23.1 mAb as a result of the in vivo treatment. At present, it appears that the loss of V/38 + T ceils was a result of T cell depletion and not TCR modulation. FACS ~ profiles generated after the in vivo administration of F23.1 did not demonstrate downregulation of either the TCR alone or the TCR in combination with CD8 ( Fig. 2) , in apparent contrast to recent studies by Teh et al. (22) or l%cha and yon Boehmer (23) . The VB8 § T lymphocytes did not begin to reappear in the spleen and axillary lymph nodes until "6 wk after F23.1 administration, which was the longest interval evaluated(data not shown). At the completion of this culture period, the CTL were analyzed for specific cytolytic activity. As shown in Fig. 3 a, depletion of the F23.1 + lymphocytes resulted in a marked decrease in the anti-H-2L a cytolytic response in comparison with the control din2 CTL, which demonstrated strong cytolytic activity against the Ld-disparate targets. In contrast, depletion of the V/38 + T lymphocytes did not alter the anti-H-2 b response (Fig. 3 b) . These data demonstrate that the ailogeneic din2 anti-L a primary response preferentially uses the Vfl8 gene family and that the in vivo depletion of these T cells abrogates this primary response. Additionally, this effect is L a specific since the depletion of Vfl8 T ceils did not affect the response to Kb/D b antigens (Fig. 3 b) . T lymphocytes in La-disparate, haplotype-mismatched and single Dk-locus-disparate skin graft rejection. Female control untreated din2 mice and din2 mice treated with 500/~g F23.1 (days -2, 0, and + 3) received two skin grafts ( Table 1 ). The right dorsal thorax was engrafted with a full thickness BALB/c (H-2 a) abdominal skin graft, and the left dorsal thorax was engrafted with a C57BL/6 (H-2 b) abdominal skin graft. Whereas F23.1-treated female din2 mice rejected the H-2 b skin grafts in a time similar to control animals, the H-2 d skin graft survival was significantly prolonged by about 10 d in comparison with controls ~ <0.01) (Fig. 4, A and B) . To properly control for nonspecific effects of the antibody treatment, din2 female mice were treated with the isotypematched mAb KJ23 that is specific for V/317. As shown in Fig. 4 C, mice treated with purified KJ23 antibody rejected La-disparate grafts in a fashion comparable with untreated control recipient mice. Thus, the above La-disparate graft prolongation observed with F23.1 was specific and attributable to the depletion of V~/8 + T lymphocytes. To further characterize the aUoantigenic specificity of this graft prolongation, transplants across other MHC disparities were also tested. To determine whether grafts differing by L d in addition to other class I and II alloantigens were affected by F23.1, treated, din2 mice were grafted with B10.HTT (K', A ', E '/k, D a, L d) skin. These skin grafts were rejected by control dm2 mice in 11.2 _+ 0.9 d, whereas the F23.1-treated din2 mice rejected these BI0.HTT skin grafts in 11.3 + 0.8 d, which is not significantly different than controls (Fig. 5 A) were grafted with skin from BALB.K (H-2k). Thus the only genetic disparity between the FI recipients and the BALRK donor is the D k locus, because they are genetically matched at other class I, class II, and non-MHC loci. All BALRK skin grafts were rejected by control and F23.1-treated (B10.AKM x drn2)Ft mice in similar fashions, (control mice rejected the BALB.K skin grafts in/1.8 + 1.0 d, whereas F23.1-treated mice rejected these grafts in 12.1 + 1.2 d) (Fig.  5 B) . These skin graft results indicate that the depletion of V/~8 + T lymphocytes does not affect allogeneic responses to all MHC antigens. Thus V/~8 + T lymphocytes play a central and spedfic role in the primary response to L d aUoantigens.
Effect of In Vivo Depletion of Vl~8 + T Lymphoc,/tes on the
Effect of In Vivo Depletion of Vr + T Lymphocytes on L ddisparate Stdn
To assess the possibility that the VB8 + T lymphocytes had repopulated the peripheral lymphoid circulation and mediated the anti-H-2L d skin allograft rejection response in the VB8-depleted recipients, flow cytometry evaluation of the peripheral lymphoid system was performed. At the completion of rejection of both the H-2 b and H-2 d skin grafts, spleen cells and draining axillary lymph node lymphocytes were harvested and evaluated for the presence of VB8 + T lymphocytes by flow cytometry. The control din2 spleen cells contained 5-8% CD8 + VB8 + T cells (Fig. 6 a) whereas F23.1-treated dm2 mice, despite rejecting an H-2 d skin graft, did not possess CD8 + V38 + T cells (Fig. 6 c) . Identical results were obtained with axillary lymph node lymphocytes indicating that the V~8 + T cells were not concentrating in the region of the graft. These results demonstrate that the V~8 + T cell population plays a dominant role in the primary response to L a and that, in the absence of a V38 T cell response, a secondary T lymphocyte population develops after a delay and effects rejection of the La-disparate skin graft.
Effect of In Vivo Depletion of V,88 + T Lymphocytes on the Secondary Anti-H-2L ~ Allogeneic
Response. Since V~8-depleted dm2 mice did ultimately reject their L~-disparate grafts, it was interesting to characterize the nature of this response. After the complete rejection of BALB/c skin grafts shown in Fig. 6 . These data demonstrating Ld-directed cytotoxicity in the V~8 + T lymphocyte-depleted host confirm that the anti-L a allogeneic response can occur after a prolonged exposure to antigen in the absence of V~/8 + T lymphocytes and suggest that lymphocytes expressing other T cell receptors not affected by the F23.1 mAb are playing a role. In support of this contention, anti-L a CTL lines from F23.1-treated mice were propagated in vitro for an additional 4 wk and shown to lack the V~8 TCR by flow cytometric analysis (data not shown). It is noteworthy that the targets used in Fig. 6 are MHC class II-negative, thus the cytotoxicity observed was presumably CD8 + CTL recognizing intact L d and not CD4 + CTL recognizing processed L d.
Effect of In Vivo Depletion of V~8 + T Lymphocytes on Ladisparate Cardiac Allografi Survival.
Because the in vivo depletion of VB8 + T lymphocytes resulted in prolonged L adisparate skin graft survival, we next attempted to extend this observation to the less immunogenic vascularized cardiac allograft by utilizing a heterotopic cardiac transplantation model. Control untreated din2 mice rejected Ld-disparate BALB/c cardiac allografts in 8.6 + 0.5 d (Fig. 7) . Histologic evaluation of BALB/c cardiac allografts removed at the complete cessation of ventricular contraction demonstrated a typical dense mononudear cell infiltration and associated myofibril necrosis consistent with allograft rejection. In contrast, the mean survival time of BALB/c cardiac allografts in din2 mice that were treated with 500 #g F23.1 on days -2, -1, +3, +25, +50, and +75 was prolonged to >100 d (p < 0.01 vs. control). Additional antibody was given to these animals on days 25, 50, and 75 to ensure that the V~8 + T cells did not repopulate the circulation. Histologic evaluation of these BALB/c hearts removed 100 d after heterotopic transplantation demonstrated healthy cardiac myocytes without mononuclear cell infiltration or evidence of tissue damage. Therefore, in the less immunogenic vascularized cardiac allograft, removal of the VB8 § T lymphocyte population eliminates the primary response and thereby allows dramatically prolonged survival of the allograft. The prolongation of BALB/c cardiac allograft survival by the depletion of VB8 § T lymphocytes in the dm2 recipient thus extends the observation to a second organ and confirms that the V~8 TCR gene family plays a pivotal role in the primary immune response to H-2L a alloantigen.
Discussion
As a model system to study the TCR gene usage of a defined aUoantigen, we have studied allorecognition of the murine L a molecule. We report here that in vivo treatment with the VBS-spedfic mAb F23.1 diminates all detectable peripheral VB8 + T lymphocytes. This in vivo depletion was found to abrogate a subsequent primary in vitro response of din2 cells to L d. Additionally, the depletion of V/~8 + T lymphocytes significantly prolonged survival of Ld-disparate skin and even more dramatically prolonged vascularized heart aliografts. This abrogation of the dm2 anti-L d response was MHC specific in that in vivo depletion of VB8 + CTL had no effect on the in vivo or in vitro response of din2 homozygous or hetero-zygous mice to other class I alloantigens. Thus, the in vivo administration of the mAb F23.1 results in a substantial MHC-specific abrogation of the primary din2 response to L d alloantigens. These findings demonstrate that TCR with VB8 segments predominate in the in vivo and in vitro primary responses to the L a alloantigen. This finding of a predominant TCR usage in allogeneic responses to MHC molecules is in agreement with certain studies (e.g., 11, 12), whereas others have reported finding high levels of TCR diversity (13) (14) (15) . The reported diversity of allorespousiveness could be explained by either structural differences among class I alloantigens (24) or their respective ligands (25) . For example, the high level ofpolymorphism among class I molecules results in '~20% differences between the amino acid residues of different K, D, or L molecules (26) . Furthermore, most of these differences are located in the otl/ot2 domains at positions where they could affect TCR recognition of class I either directly or indirectly via ligand binding (27) . Given that the L d molecule is as different from D d and K d molecules as they are from each other (26) , the lack of diversity in the TCR response to L a alloantigens is probably not due to insufficient polymorphism. Another contributing factor in the complexity of the alloresponse to class I could be the role of the bound peptide ligand. Although still somewhat controversial, several studies indicate that certain aUoreactive (28) and xenoreactive (29) TCR to class I can discriminate selfpeptide llgands. Furthermore, a given class I molecule is dearly capable of binding numerous sdf-peptide ligands (30) . Therefore, if the bound peptide ligand plays a role in allorecognition, diversity in the TCR gene family usage would be anticipated. Given that L a molecules, like K and D alloantigens, have been shown to bind several different immunogenic or sdf-peptides (31) (32) (33) , the lack of TCR diversity of L a alloantigens is presumably not due to its inability to bind a variety of ligands. Thus, there are no obvious structural differences between L a and other dass I molecules and their respective ligands that might explain why the alloresponse of din2 mice to L d should show such a limited V~8 usage. However, based on the recent modal of Davis and Bjorkman (7), speculations can be made that might explain the predominance of V~88 in TCR recognition of L d.
Although the precise manner by which TCR and class I-peptide interact is unclear, a very intriguing model has been recently proposed. Even though TCR molecules have not yet been crystallized, based on structural similarities with Ig, their respective V domains are likely to display comparable folding. Furthermore, the three hypervariable regions of Ig (CDR1-3), known to form the principal contact points of Ig with antigen, are located at equivalent locations in TCR gene products. Given these similarities between TCR and Ig, Davis and Bjorkman (7) proposed a modal of how MHC molecules and TCR might interact. In this model, the CDR1 and CDR2 regions of Vc~ and V~/of the TCR would interact with the ot hdical portions of the r dass I molecule. Furthermore, the CDR3 region located in the V(D)J junction would interact with bound peptide (34) . Indeed, there are several findings consistent with this modal (cf 11, 12) . In the context of this model, speculations can be made as to why the L a alloresponse might show a predominant V~8 usage. Perhaps the predominance of VB8 recognition of L a is determined by the structure of its c~ helical regions independent of the bound peptide ligand. Fortuitously, the CDK1 and CDR2 regions of V158 could have an at~nity for surface residues in the o~ helical regions of L d. This explanation is supported by the observations that V~8 predominates in both alloreactive (data presented here) and syngeneic peptidespecific responses restricted to L a in BALB/c mice. In these studies of La-restricted syngeneic responses, Kodewald et al. (8) demonstrated a 3-5-fold higher L a-restricted CTL precursor frequency in V/58 + T lymphocytes compared with V158-T lymphocytes after infection with CMV; and Solheim et al. (manuscript submitted for publication) found a dominant usage of VB8 by La-restricted CTL clones specific for the tuna-peptide. Thus V138 predominates in both allogeneic and at least certain peptide-specific responses restricted by L a in mice of the BALB/c genetic background. It will be very interesting to determine whether this extends to mouse strains of other genetic backgrounds.
An alternative explanation for the predominance of V138 usage is that it is determined by the peptide ligands bound to L a. Although L d presents many different peptides, perhaps a high proportion of alloreactive CTL to L a recognize the same dominant sdf-peptide or peptides of a common structural motif. However, predominant V138 usage has also been observed in syngeneic peptide-specific responses to L d, and these latter CTL display exquisite peptide specificity. Furthermore, the primary region of the TCR thought to interact with the bound peptide is CDK3 which is located in the junctional region, not the V segment alone (34) . Thus, it appears more likely that the predominant usage of VB8 found in responses restricted by L a is independent of the bound peptide. Regardless of which of the above explanations is correct, the predominance of V~8 usage reported here provides an important insight into TCK recognition of an allogeneic dass I molecule. It was noted by Davis and Bjorkman (7) that the relative sizes of the interactive surfaces of MHC and TCK would allow binding in different registers along the MHC ol helices. Thus the V genes employed by different T cells restricted to the same MHC molecule would not be expected to be identical. By contrast, our data would suggest that at least V138 and L a interact primarily along a single register as defined by the predominance of VB8 in allogeneic and MHC-restricted responses.
In conclusion, the findings here may have clinical relevance for the design of transplantation immunotherapies. Previous studies of end stage rejection of transplanted tissues have demonstrated heterogeneous TCR usages. This heterogeneous response is predictable however, based on the fact that at end stage rejection there would be recruitment of large numbers of T lymphocyte specificities due to both nonspecific factors produced as a result of inflammatory processes and specific recruitment ofT lymphocytes reactive with potentially tissuespecific cryptic epitopes exposed as a result of tissue destruction. Recent reports in the human have indicated that, similar to the data presented here, initial rejection episodes demonstrate a preferential TCK usage for the bulk of the response (12) . Therefore, if specific TCK therapies could be designed to block the initial predominant rejection response, perhaps the second line of recruitment and rejection may be more easily managed with lower doses of conventional immunotherapies and thereby decrease host susceptibility to opportunistic infections and malignancies. In addition, EAE has been treated with TCR peptides derived from the predominantly selected variable regions (35, 36) . Recent data reported by Lehmann et al. (37) supports our hypothesis that if the first line immune response is abrogated early, the secondary response may also be downregulated. Lehmann et al. (37) demonstrated in the experimental allergic encephalitis model specific peptide therapy during primary disease induction processes inactivates the primary TCK donally restricted effector cells, abrogating the inflammatory reaction in the central nervous system, a prerequisite for second wave priming. However, after determinant spreading has occurred, as a result of central nervous system inflammatory processes, anticlonotypic therapy may no longer be effective in therapeutically managing the diversified autoreactive T cell pool in more advanced disease. Indeed, our preliminary studies indicate that a peptide derived from the CDR2 region of V138.2 can prolong Ld-disparate allografts. Thus peptide therapy may also be effective for the prevention and treatment of allograft rejection when a predominant TCK gene family usage can be identified.
